Beam Therapeutics Stock Fundamentals
| BEAM Stock | USD 24.23 0.83 3.31% |
Beam Therapeutics fundamentals help investors to digest information that contributes to Beam Therapeutics' financial success or failures. It also enables traders to predict the movement of Beam Stock. The fundamental analysis module provides a way to measure Beam Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Beam Therapeutics stock.
At this time, Beam Therapeutics' Total Revenue is very stable compared to the past year. As of the 15th of March 2025, Reconciled Depreciation is likely to grow to about 33.2 M, while Selling General Administrative is likely to drop about 60.1 M. Beam | Select Account or Indicator |
Beam Therapeutics Company Current Valuation Analysis
Beam Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Beam Therapeutics Current Valuation | 1.81 B |
Most of Beam Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Beam Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Beam Current Valuation Historical Pattern
Today, most investors in Beam Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Beam Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Beam Therapeutics current valuation as a starting point in their analysis.
Beam Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Beam Therapeutics has a Current Valuation of 1.81 B. This is 87.38% lower than that of the Biotechnology sector and 60.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 89.1% higher than that of the company.
Beam Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Beam Therapeutics's current stock value. Our valuation model uses many indicators to compare Beam Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Beam Therapeutics competition to find correlations between indicators driving Beam Therapeutics's intrinsic value. More Info.Beam Therapeutics is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . At this time, Beam Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Beam Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Beam Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Beam Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Beam Therapeutics could also be used in its relative valuation, which is a method of valuing Beam Therapeutics by comparing valuation metrics of similar companies.Beam Therapeutics is currently under evaluation in current valuation category among its peers.
Beam Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Beam Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Beam Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Beam Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (3.33) % | ||||
| Current Valuation | 1.81 B | ||||
| Shares Outstanding | 99.84 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 79.06 % | ||||
| Number Of Shares Shorted | 9.24 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 3.41 X | ||||
| Price To Sales | 38.09 X | ||||
| Revenue | 63.52 M | ||||
| Gross Profit | (304.04 M) | ||||
| EBITDA | (415.57 M) | ||||
| Net Income | (376.74 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 161.43 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.05 X | ||||
| Cash Flow From Operations | (347.25 M) | ||||
| Short Ratio | 7.51 X | ||||
| Earnings Per Share | (4.58) X | ||||
| Price To Earnings To Growth | (2.30) X | ||||
| Target Price | 49.07 | ||||
| Number Of Employees | 483 | ||||
| Beta | 1.91 | ||||
| Market Capitalization | 2.42 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 696.08 M | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
| Net Asset | 1.1 B |
About Beam Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Beam Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beam Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beam Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 108.9 M | 65.9 M | |
| Cost Of Revenue | 503 M | 528.1 M | |
| Total Revenue | 63.5 M | 87.1 M | |
| Stock Based Compensation To Revenue | 0.30 | 0.29 | |
| Sales General And Administrative To Revenue | 1.76 | 1.67 | |
| Research And Ddevelopement To Revenue | 5.79 | 5.50 | |
| Capex To Revenue | 0.14 | 0.13 | |
| Revenue Per Share | 0.77 | 0.98 | |
| Ebit Per Revenue | (6.54) | (6.87) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Beam Therapeutics Piotroski F Score and Beam Therapeutics Altman Z Score analysis. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.58) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.